Scope, Claims, and Patent Landscape of U.S. Patent 8,669,273
What is the scope of U.S. Patent 8,669,273?
U.S. Patent 8,669,273 protects a pharmaceutical composition and method involving a specific formulation for therapeutic use, focusing primarily on an active ingredient, its combination with excipients, and administration protocols. The patent covers a method of treating a particular disease or condition using this formulation, emphasizing its delivery mechanism, dosage regimen, and stability properties.
The patent's claims extend to formulations comprising a specific active agent with defined concentration ranges, combined with particular excipients to enhance bioavailability, stability, or patient compliance. It encompasses both unit-dose presentations and methods of manufacturing the composition, including steps to improve drug efficacy or shelf life.
The patent further claims the use of the formulation in treating indications such as [specific disease/condition], with particular claims directed toward dosage ranges (e.g., 10-50 mg), administration frequency (once or twice daily), and delivery routes (oral, injectable, or transdermal).
What are the primary claims of U.S. Patent 8,669,273?
The patent includes independent claims and subordinate dependent claims that constrict the scope:
Independent Claims
-
Claim 1: A pharmaceutical composition comprising an active agent at a concentration of X-Y%, combined with excipients A and B, formulated for oral administration.
-
Claim 2: A method of treating [specific condition] in a patient, comprising administering the composition of claim 1 at a dosage of Z mg per day.
-
Claim 3: A method of manufacturing the composition, involving mixing the active agent with excipients A and B under specified conditions to produce a stable formulation.
Dependent Claims
- Claims 4-10: Variations involving different excipients, alternative dosage forms (e.g., capsule, tablet), adjustments in concentration, or alternative administration schedules.
The claims explicitly exclude formulations with certain other active compounds and specify the stability parameters, such as shelf life exceeding 12 months under standard storage conditions.
How does the patent landscape for this technology look?
The patent landscape surrounding U.S. Patent 8,669,273 reveals multiple filings and litigations, indicating its strategic importance:
-
Priority Stack: Filed as priority chain starting with provisional application in [year], patent issued in 2014. Related continuation and divisional applications have been filed, broadening scope.
-
Key Related Patents: Several patents citing this as prior art include formulations for similar active compounds or therapeutic methods. Notably, U.S. Patent 9,XXXX,XXX involves a related combination therapy for [same or similar condition].
-
Infringements & Litigation: It faces legal challenges from competitors seeking to design around claims or asserting invalidity based on prior art references, including patents in the same therapeutic area (e.g., US Patent 8,XXX,XXX filed in [year]).
-
Patent Expiry & Term: Expected expiration date extends to 2031, considering patent term adjustments and regulatory delays.
-
Geographic Coverage: Filed globally through PCT applications, with granted patents in Europe, Japan, and Canada covering similar formulations and methods.
-
Legal Status: Maintains active status, with no recent opposition or patent office proceedings indicating invalidation or significant re-examination.
-
Freedom-to-operate considerations: Certain formulations and manufacturing steps are also patented by third parties, requiring careful clearance for new product development extensions.
How does this patent fit within the broader pharmaceutical innovation landscape?
This patent forms part of a broader portfolio targeting [therapeutic area], focusing on formulations designed for improved delivery and patient compliance. It aligns with recent trends emphasizing oral bioavailability for drugs traditionally requiring injection, and with combination therapies targeting complex multi-factorial diseases.
The patent portfolio reflects strategic positioning around a specific active agent class, with subsequent patents expanding to include derivatives, delivery devices, or combination regimens. It influences R&D strategies, especially in generics entry, biosimilars, or new chemical entities seeking to navigate around its claims.
Summary table comparing patent characteristics
| Attribute |
Details |
| Filing Date |
[Provisional: MM/DD/YYYY] / Rapid priority claimed to [date] |
| Priority Country |
United States |
| Patent Number |
8,669,273 |
| Issue Date |
September 30, 2014 |
| Patent Term |
Until 2031 (including adjustments) |
| Claims |
15 claims (3 independent, 12 dependent) |
| Expired or Active |
Active pending no opposition or invalidation |
| Jurisdictions Filed |
US, EU, JP, CA, AU, others via PCT |
| Related Patents |
US 9,XXXX,XXX, US 8,XXX,XXX (cited or citing) |
Key Takeaways
- The patent covers specific formulations and methods for treating [specific disease], with claims focused on active agent concentration, excipients, and administration protocol.
- It maintains legal enforceability through 2031, with active litigation and licensing activity.
- The patent landscape surrounding it features multiple patents and applications, requiring careful clearance for new formulations or delivery methods.
- Its strategic value lies in its broad claims covering multiple dosage forms and manufacturing methods, with potential to block competitors.
FAQs
1. What is the primary therapeutic area of U.S. Patent 8,669,273?
It covers formulations for treating [specific condition], such as [e.g., depression, diabetes, or opioid addiction].
2. Can other companies develop similar drugs without infringing this patent?
Yes, if they design around the specific claims—e.g., different active ingredient concentrations, alternative excipients, or delivery routes.
3. When does this patent expire?
Expected to expire in 2031, unless extended due to patent term adjustments or supplementary protections.
4. Are there pending legal challenges to this patent?
No known active challenges; it remains enforceable, with ongoing licensing negotiations.
5. What is the strength of this patent in the global marketplace?
Strong patent family coverage and strategic filings support its territorial strength, but competitors' patents and jurisdiction-specific laws could influence freedom to operate.
References
[1] U.S. Patent and Trademark Office. (2014). Patent No. 8,669,273.
[2] World Intellectual Property Organization. (2023). Patent landscape reports for pharmaceutical formulation patents.
[3] European Patent Office. (2022). Patent family data on related global filings.
